Which Second-Line Therapy Is Better for Right-Sided CRC?
TOPLINE:
Continuing anti-VEGF therapy plus chemotherapy in the second-line setting led to a small but nonsignificant increase in overall survival in patients with right-sided, RAS/RAF wild-type metastatic colorectal cancer (CRC) compared to patients who received anti-epidermal growth factor receptor (EGFR) therapy plus chemotherapy.
METHODOLOGY:
Despite limited evidence, guidelines recommend anti-EGFR therapy plus chemotherapy in the second line for patients with RAS/RAF wild-type, right-sided tumors who did not previously receive anti-EGFR therapy.
To assess whether this is the best option, the current study compared the effectiveness of continuing chemotherapy plus anti-VEGF in the second-line or using anti-EGFR plus chemotherapy.
Researchers used electronic health record data from 280 community oncology clinics in the US.
The analysis included 444 patients (median age, 65 years) with RAS/RAF wild-type, right-sided metastatic CRC who received first-line chemotherapy plus anti-VEGF therapy, followed by second-line anti-VEGF therapy (n = 269) or anti-EGFR therapy (n = 175) with chemotherapy.
Researchers then compared overall survival in these two groups.
TAKEAWAY:
Compared with the anti-VEGF therapy group, the anti-EGFR therapy group demonstrated a nonsignificant increased risk for death (hazard ratio [HR], 1.24; P = .10).
The median overall survival was 15.3 months with anti-VEGF therapy vs 12.0 months with anti-EGFR therapy.
The findings were consistent with first-line trial results, showing nonsignificant worse overall survival with anti-EGFR vs anti-VEGF therapy in right-sided tumors (HR, 1.09).
IN PRACTICE:
Among patients with RAS/RAF wild-type, right-sided metastatic CRC who received first-line chemotherapy plus anti-VEGF therapy, these findings 'provide some evidence for continuing anti-VEGF therapy in the second line, although the result was not statistically significant,' the authors wrote.
SOURCE:
This study, led by Nishwant Swami, MD, MPH, Hospital of the University of Pennsylvania, Philadelphia, was published online in JAMA Network Open.
LIMITATIONS:
This study was limited by possible unmeasured confounding factors and had limited statistical power due to the relatively small proportion of mCRC cases that were right-sided and RAS/RAF wild-type.
DISCLOSURES:
No funding information was provided for this study. Several authors reported receiving grants and personal fees and having other ties with various sources.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
This dieting approach may be more effective than intermittent fasting, scientists say
Alternate-day fasting works better at boosting metabolism compared to both calorie restriction and intermittent fasting, a new study suggests. Nearly 2.5 billion adults, or about 43 per cent of the global adult population, are overweight, with around 890 million living with obesity, according to the World Health Organization. Doctors recommend weight loss for this segment of the population to reduce metabolic risk factors like high blood pressure, elevated cholesterol and increased blood sugar levels, all of which contribute to diabetes and heart disease. Intermittent fasting, which involves cycling between periods of eating and fasting on a regular schedule, is sometimes recommended as an alternative to traditional calorie-restricted diets for weight loss. This may include time-restricted eating, typically involving a 16-hour fasting period followed by an eight-hour eating window. Another form of fasting is alternate-day fasting, which involves a 24-hour fast every other day. But the health benefits of various forms of fasting compared to continuous caloric restriction and an unrestricted diet have remained largely unclear so far. In a new study, researchers analysed the results of 99 randomised clinical trials involving 6,582 adult men and women to compare the effects of intermittent fasting diets with continuous calorie restriction or unrestricted diets on body weight and metabolic risk factors. The study participants had an average body mass index of 31, and nearly 90 per cent had pre-existing health conditions. Researchers found that alternate-day fasting was the only dietary strategy which provided a modest benefit in reducing body weight compared to continuous calorie restriction. This form of fasting was also associated with lower levels of total and LDL, or 'bad' cholesterol compared to time-restricted eating. However, researchers noted that even alternate-day fasting did not meet the clinically significant threshold of at least 2kg of weight loss for individuals with obesity. They cautioned that 'longer-duration trials are needed to further substantiate these findings'. 'Additional high quality randomised clinical trials, with extended durations beyond 52 weeks, are needed to elucidate the long-term effects of these dietary strategies,' they said in the study, 'with greater emphasis between intermittent fasting and its impact on cardiometabolic health across diverse populations.' For now, they said, alternate-day fasting could be added to the therapeutic toolkit for managing weight and metabolic health. 'Intermittent fasting does not aim to replace other dietary strategies, but to integrate and complement them within a comprehensive, patient-centered nutritional care model,' they noted.
Yahoo
29 minutes ago
- Yahoo
Hims & Hers, healthcare stocks, BNY: Trending Tickers
Novo Nordisk (NVO) ended its weight-loss drug partnership with Hims & Hers (HIMS), sending shares of both companies lower. UnitedHealth (UNH), CVS (CVS), and Cigna (CI) are in focus as health insurers are set to simplify the authorization process, according to AHIP. BNY (BNY) is reportedly considering a merger with Northern Trust (NTRS), according to the Wall Street Journal. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Hims & Hers stock plummets after Novo Nordisk ends Wegovy direct sales deal
Hims & Hers (HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk (NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth platform. Novo Nordisk said that Hims & Hers was breaking the law by continuing to sell copycat semaglutide, the key ingredient in Wegovy, alongside Novo's branded drugs. "Hims & Hers ... has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization,'" Novo said in a statement Monday. The duo announced a collaboration last month that would allow patients to directly purchase Wegovy through Hims' telehealth platform. The agreement followed a growing trend among pharma companies, including Novo's competitor Eli Lilly (LLY) to fill the access gap after copycat, or compounded, GLP-1s were forced off the market. Compounded drugs were available when Lilly and Novo struggled to produce enough of their GLP-1s to meet the unexpected and unprecedented demand spike in the weight-loss market. The Food and Drug Administration (FDA) allows for copycats to be sold when a drug is in short supply without undergoing the same trial requirements as the branded drugs. Since the shortage has ended for both companies' drugs, some compounding pharmacies have continued to make copycats — mostly for Novo's semaglutide. They intend to continue and are allowed to do so due to a loophole that allows patients to have access to "personalized" medicine if they need adjustments to a branded product for reasons like tolerability or allergies. Lilly is also faced with how to manage some telehealth platforms that continue to offer compounded products, including Novo Nordisk's, which Lilly included in its concerns. Hims & Hers did not immediately respond to a request for comment. In addition to the latest ding to the company's stock, investors are expecting Hims & Hers to grow at a slower clip than in the recent past. Hims has been riding the highs (and sometimes volatile swings) in GLP-1 news, especially as it relates to the availability of the copycat drugs. But it is also showing weakness in overall subscriptions to its telehealth platform, according to Bank of America analyst Allen Lutz. Revenue growth year over year has slowed sharply from roughly 45% in the third quarter of 2024 to 29% in the first quarter of this year. In addition, the Federal Trade Commission (FTC) will implement a new rule in July making it easier for customers to cancel subscriptions with one click, which "could impact HIMS churn by simplifying subscription cancellations," Lutz said. Meanwhile, pressure from Congress and the federal government to end direct-to-consumer marketing for pharmaceutical sales could impact Hims, which faced backlash after it advertised compounded GLP-1s during the Super Bowl in February. But there is one potential bright spot, according to Lutz. Hormone replacement therapy (HRT), a potentially $3 billion to $10 billion market, could add $4 million to $12 million for Hims in 2025. "HIMS has a strong history of scaling new categories quickly and hormone replacement therapy (HRT) is the next opportunity," Lutz wrote. "HIMS' DTC [direct-to-consumer] offering is likely to expand the current addressable market over time given strong brand recognition." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
